Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes
Sponsored by Robin Goland, MD, in collaboration with JDRF
Focus Areas: Beta Cell Therapies
What is This Study?
In this Phase 2 trial, tauroursodeoxycholic Acid (TUDCA)—an oral medication approved in Europe for the treatment of gall stones and liver disease—is being given to participants aged 18-45 who have been diagnosed with type 1 diabetes within the past 100 days. The study is hoping to demonstrate whether the drug can protect the destruction of beta cells by strengthening the cells’ capacity to withstand the immune attack.
Why do We Care?
Preserving beta cells is key to preventing and slowing the progression of diabetes. Many treatments currently being researched involve immunotherapy drugs that are taken via infusion. If TUDCA—an oral medication—is shown to protect beta cells, it could be a huge leap forward towards beta cell regeneration research, and a pathway to a less strenuous way to prevent and delay type 1 diabetes (T1D).
When Might we See Results?
Results for this study are expected in late 2020.
Stay tuned for in-depth coverage from Beyond Type 1 on the results of this study. To learn more about this trial click here